Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Abstract 7150: Molecular insights into the oncogenic influence between mutant HER3, mutant KRAS, and their synergistic interplay in colorectal cancer pathogenesis

Mary K. Kilroy, Briley Park, Rosalin Mishra, Wasim Feroz, Cecilia Wischmeier, Joan T. Garrett

Cancer Res (2024) 84 (6_Supplement): 7150.

https://doi.org/10.1158/1538-7445.AM2024-7150

Published: 22 March 2024

View article titled, Abstract 7150: Molecular insights into the oncogenic influence between mutant HER3, mutant KRAS, and their synergistic interplay in colorectal cancer pathogenesis

Journal Articles

Abstract 5914: Non-muscle myosin IIA as a promising therapeutic target in breast cancer

Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Joan T. Garrett

Cancer Res (2024) 84 (6_Supplement): 5914.

https://doi.org/10.1158/1538-7445.AM2024-5914

Published: 22 March 2024

View article titled, Abstract 5914: Non-muscle myosin IIA as a promising therapeutic target in breast cancer

Journal Articles

Abstract 3916: role of her3 v104l mutation on tumor growth and her3 stabilization

Rosalin Mishra, Mary Kate Kilroy, Wasim Feroz, Hima Patel, Samar Alanazi, Joan T. Garrett

Cancer Res (2023) 83 (7_Supplement): 3916.

https://doi.org/10.1158/1538-7445.AM2023-3916

Published: 04 April 2023

View article titled, Abstract 3916: role of her3 v104l mutation on tumor growth and her3 stabilization

Journal Articles

Abstract 3988: The role of HER3 mutations in the progression of colon cancer and modulation of drug sensitivity and resistance

Mary K. Kilroy, Rosalin Mishra, Anastasia Stupecki, Wasim Feroz, Samar Alanazi, Joan T. Garrett

Cancer Res (2023) 83 (7_Supplement): 3988.

https://doi.org/10.1158/1538-7445.AM2023-3988

Published: 04 April 2023

View article titled, Abstract 3988: The role of HER3 mutations in the progression of colon cancer and modulation of drug sensitivity and resistance

Journal Articles

Abstract 5661: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers

Samar M. Alanazi, Rosalin Mishra, Hima Patel, Mary K. Kilroy, Joan T. Garrett

Cancer Res (2022) 82 (12_Supplement): 5661.

https://doi.org/10.1158/1538-7445.AM2022-5661

Published: 15 June 2022

View article titled, Abstract 5661: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers

Journal Articles

Abstract 5412: Role of her3 mutations on breast cancer oncogenesis

Rosalin Mishra, Mary Kate Kilroy, Hima Patel, Samar Alanazi, Joan T. Garrett

Cancer Res (2022) 82 (12_Supplement): 5412.

https://doi.org/10.1158/1538-7445.AM2022-5412

Published: 15 June 2022

View article titled, Abstract 5412: Role of her3 mutations on breast cancer oncogenesis

Journal Articles

Abstract 5356: RIDR-PI-103, ROS-activated PI3K inhibitor prodrug inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor resistant BRAF-mutant melanoma cells

Hima Patel, Rosalin Mishra, Adam Wier, Nazanin Mokhtarpour, Edward J. Merino, Joan T. Garrett

Cancer Res (2022) 82 (12_Supplement): 5356.

https://doi.org/10.1158/1538-7445.AM2022-5356

Published: 15 June 2022

View article titled, Abstract 5356: RIDR-PI-103, ROS-activated PI3K inhibitor prodrug inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor resistant BRAF-mutant melanoma cells

Journal Articles

Abstract P5-10-05: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers

Samar M Alanazi, Rosalin Mishra, Hima Patel, Long Yuan, Mary Kate Kilroy, Joan T Garrett

Cancer Res (2022) 82 (4_Supplement): P5-10-05.

https://doi.org/10.1158/1538-7445.SABCS21-P5-10-05

Published: 15 February 2022

View article titled, Abstract P5-10-05: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers

Journal Articles

Abstract 1894: Role of IGF1R in mediating resistance to MAPK pathway inhibitors in BRAF-mutant melanoma

Hima Patel, Rosalin Mishra, Natasa Broit, Nour Yacoub, Long Yuan, Samar Alanazi, Nicholas Hayward, Peter Johansson, Joan T. Garrett

Cancer Res (2020) 80 (16_Supplement): 1894.

https://doi.org/10.1158/1538-7445.AM2020-1894

Published: 15 August 2020

View article titled, Abstract 1894: Role of IGF1R in mediating resistance to MAPK pathway inhibitors in BRAF-mutant melanoma

Journal Articles

Abstract P3-10-04: Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer

Rosalin Mishra, Hima Patel, Haizhou Zhu, Aaron White, Long Yuan, Samar Alanazi, Kurt Hodges, Edward J Merino, Joan T Garrett

Cancer Res (2020) 80 (4_Supplement): P3-10-04.

https://doi.org/10.1158/1538-7445.SABCS19-P3-10-04

Published: 15 February 2020

View article titled, Abstract P3-10-04: Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer

Journal Articles

Abstract 389: Role of her3 signaling pathways in er+ and her2+ breast cancers

Rosalin Mishra, Samar Alanazi, Hima Patel, Long Yuan, Joan T. Garrett

Cancer Res (2019) 79 (13_Supplement): 389.

https://doi.org/10.1158/1538-7445.AM2019-389

Published: 01 July 2019

View article titled, Abstract 389: Role of her3 signaling pathways in er+ and her2+ breast cancers

Journal Articles

Abstract 1896: Patient-derived HER3 mutations transform ER+ and HER2+ breast cancer cells via MAPK pathway activation

Rosalin Mishra, Samar Alanazi, Long Yuan, Thomas Solomon, Tarjani M. Thaker, Natalia Jura, Joan T. Garrett

Cancer Res (2018) 78 (13_Supplement): 1896.

https://doi.org/10.1158/1538-7445.AM2018-1896

Published: 01 July 2018

View article titled, Abstract 1896: Patient-derived HER3 mutations transform ER+ and HER2+ breast cancer cells via MAPK pathway activation

Journal Articles

Abstract LB-212: HER2-overexpressing breast cancer xenografts amplify FGFR signaling upon acquisition of resistance to dual blockade with trastuzumab and lapatinib

Joan T. Garrett, Jennifer Becker, Mónica Valeria Estrada, Carlos L. Arteaga

Cancer Res (2014) 74 (19_Supplement): LB-212.

https://doi.org/10.1158/1538-7445.AM2014-LB-212

Published: 01 October 2014

View article titled, Abstract LB-212: HER2-overexpressing breast cancer xenografts amplify FGFR signaling upon acquisition of resistance to dual blockade with trastuzumab and lapatinib

Journal Articles

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

Joan T. Garrett, Cammie R. Sutton, Richard Kurupi, Carl Uli Bialucha, Seth A. Ettenberg, Scott D. Collins, Qing Sheng, Jerry Wallweber, Lisa DeFazio-Eli, Carlos L. Arteaga

Cancer Res (2013) 73 (19): 6013–6023.

https://doi.org/10.1158/0008-5472.CAN-13-1191

Published: 01 October 2013

View article titled, Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

Includes: Supplementary data

Journal Articles

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

Cancer Res (2013) 73 (19): 6024–6035.

https://doi.org/10.1158/0008-5472.CAN-13-1198

Published: 01 October 2013

View article titled, An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

Includes: Supplementary data

Journal Articles

Abstract 5461: A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors .

Joan T. Garrett, Cammie R. Sutton, Carl Uli Bialucha, Seth A. Ettenberg, Jerry Wallweber, Lisa DeFazio-Eli, Carlos L. Arteaga

Cancer Res (2013) 73 (8_Supplement): 5461.

https://doi.org/10.1158/1538-7445.AM2013-5461

Published: 15 April 2013

View article titled, Abstract 5461: A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors .

Journal Articles

Abstract 3867: Dual blockade of HER2 in HER2-overexpressing tumor cells does not eliminate HER3 function completely: Clinical implications

Joan T. Garrett, Cammie R. Sutton, Rebecca S. Cook, Carlos L. Arteaga

Cancer Res (2012) 72 (8_Supplement): 3867.

https://doi.org/10.1158/1538-7445.AM2012-3867

Published: 15 April 2012

View article titled, Abstract 3867: Dual blockade of HER2 in HER2-overexpressing tumor cells does not eliminate HER3 function completely: Clinical implications

Journal Articles

ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis

Rebecca S. Cook, Joan T. Garrett, Violeta Sánchez, Jamie C. Stanford, Christian Young, Anindita Chakrabarty, Cammie Rinehart, Yixian Zhang, Yaming Wu, Lee Greenberger, Ivan D. Horak, Carlos L. Arteaga

Cancer Res (2011) 71 (11): 3941–3951.

https://doi.org/10.1158/0008-5472.CAN-10-3775

Published: 31 May 2011

View article titled, ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis

Includes: Supplementary data

NARROW

Abstract 7150: Molecular insights into the oncogenic influence between mutant HER3, mutant KRAS, and their synergistic interplay in colorectal cancer pathogenesis

Abstract 5914: Non-muscle myosin IIA as a promising therapeutic target in breast cancer

Abstract 3916: role of her3 v104l mutation on tumor growth and her3 stabilization

Abstract 3988: The role of HER3 mutations in the progression of colon cancer and modulation of drug sensitivity and resistance

Abstract 5661: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers

Abstract 5412: Role of her3 mutations on breast cancer oncogenesis

Abstract 5356: RIDR-PI-103, ROS-activated PI3K inhibitor prodrug inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor resistant BRAF-mutant melanoma cells

Abstract P5-10-05: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers

Abstract 1894: Role of IGF1R in mediating resistance to MAPK pathway inhibitors in BRAF-mutant melanoma

Abstract P3-10-04: Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer

Abstract 389: Role of her3 signaling pathways in er+ and her2+ breast cancers

Abstract 1896: Patient-derived HER3 mutations transform ER+ and HER2+ breast cancer cells via MAPK pathway activation

Abstract LB-212: HER2-overexpressing breast cancer xenografts amplify FGFR signaling upon acquisition of resistance to dual blockade with trastuzumab and lapatinib

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

Abstract 5461: A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors .

Abstract 3867: Dual blockade of HER2 in HER2-overexpressing tumor cells does not eliminate HER3 function completely: Clinical implications

ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only